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BAG5 Inhibits Parkin and Enhances
Dopaminergic Neuron Degeneration
loss of dopaminergic neurons in the substantia nigra
pars compacta (SNpc) (Lang and Lozano, 1998). Protein
aggregates known as Lewy bodies (LBs) are pathologi-
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ated with autosomal recessive juvenile Parkinson’s dis-
ease (AR-JPD) results in the loss of parkin E3 function
Summary (Imai et al., 2000, 2001; Shimura et al., 2000; Zhang et
al., 2000), which likely leads to UPS dysfunction and the
Loss-of-function mutations in the parkin gene, which accumulation of parkin substrates, resulting in neurode-
encodes an E3 ubiquitin ligase, are the major cause generation (Giasson and Lee, 2003). Indeed, overex-
of early-onset Parkinson’s disease (PD). Decreases in pression of parkin suppresses neurodegeneration asso-
parkin activity may also contribute to neurodegenera- ciated with UPS dysfunction (Petrucelli et al., 2002) or
tion in sporadic forms of PD. Here, we show that bcl-2- endoplasmic reticulum (ER) stress (Imai et al., 2001;
associated athanogene 5 (BAG5), a BAG family mem- Yang et al., 2003), whereas targeted decreases in parkin
ber, directly interacts with parkin and the chaperone expression augment cell death (Petrucelli et al., 2002;
Hsp70. Within this complex, BAG5 inhibits both parkin Yang et al., 2003).
E3ubiquitin ligaseactivity andHsp70-mediated refold- In brain, parkin associates with the molecular chaper-
ing of misfolded proteins. BAG5 enhances parkin se- one heat shock protein 70 (Hsp70) (Imai et al., 2002),
questration within protein aggregates and mitigates and both Hsp70 (Auluck et al., 2002; McLean et al., 2002)
parkin-dependent preservation of proteasome func- and parkin (Schlossmacher et al., 2002) are found in LBs
tion. Finally, BAG5 enhances dopamine neuron death in sporadic PD. Hsp70 prevents the formation of protein
in an in vivo model of PD, whereas a mutant that inhib- aggregates (Adachi et al., 2003; Chan et al., 2000; Mu-
its BAG5 activity attenuates dopaminergic neurode- chowski et al., 2000) and is neuroprotective in both Dro-
generation. This contrastswith theantideath functions sophila (Auluck et al., 2002; Chan et al., 2000; Warrick
ascribed to BAG family members and suggests a po- et al., 1999) and mammalian models (Adachi et al., 2003;
tential role for BAG5 in promoting neurodegeneration Cummings et al., 2001) of neurodegenerative disease.
in sporadic PD through its functional interactions with The role of parkin and Hsp70 in sporadic PD is not
parkin and Hsp70. clearly understood. However, it is possible that loss of
parkin (Ardley et al., 2003; Winklhofer et al., 2003) and
Introduction Hsp70 (Sherman and Goldberg, 2001) function may oc-
cur through their sequestration in LBs as a result of UPS
Parkinson’s disease (PD) is a common neurodegenera- dysfunction and cellular stress. It is also possible that
tive disease that is characterized by the progressive negative modulators of parkin and Hsp70 exist and con-
tribute to the pathogenesis of sporadic PD. Indeed, it
has been recently shown that S-nitrosylation of parkin*Correspondence: lozano@uhnres.utoronto.ca
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results in the inhibition of parkin E3 activity both in vitro
and in vivo, providing a possible mechanistic link be-
tween the genetic and sporadic forms of PD (Chung et
al., 2004; Yao et al., 2004).
BAG1, a Hsp70 interacting protein that contains a
prototypic BAG domain at its C terminus, was cloned
based on its synergistic interaction with bcl-2 (Taka-
yama et al., 1995) and is generally considered to confer
resistance to cell death (Takayama and Reed, 2001).
BAG1 functions as a cochaperone of Hsp70 through the
interaction of its BAG domain and the ATPase domain
of Hsp70 (Briknarova et al., 2001; Hohfeld and Jentsch,
1997; Sondermann et al., 2001; Takayama et al., 1997;
Zeiner et al., 1997). There are currently six known human
BAG family members (BAG1–6), and homologs have
been identified in yeast, invertebrates, mammals, and
plants (Takayama and Reed, 2001). BAG5 is the only
BAG family member that is predicted to contain multiple
BAG domains and currently remains uncharacterized.
Aside from the formation of the BAG-Hsp70 complex,
BAG proteins functionally interact with a variety of bind-
ing partners and coordinate diverse cellular processes
such as stress signaling (Song et al., 2001), cell division,
cell death, and cell differentiation (Takayama and
Reed, 2001).
Here, we show that BAG5, a BAG domain-containing
family member, interacts with both Hsp70 and parkin
with deleterious functional consequences. Through
these interactions, BAG5 inhibits Hsp70 chaperone ac-
tivity and parkin E3 ubiquitin ligase activity and en-
hances the sequestration of parkinwithin LB-like protein
aggregates. In contrast, short hairpin-mediated depres-
sion of BAG5 expression decreases the sequestration
of parkin within protein aggregates. Furthermore, BAG5
also mitigates parkin-mediated preservation of protea-
some function and inhibition of cell death. Finally, we
show that targeted expression of BAG5 in an in vivo
model of PD enhances dopaminergic neurodegenera-
tion, whereas a mutant form of BAG5 that can inhibit
BAG5 function results in enhanced cell survival.
Results
BAG5 Expression Is Induced in Dopaminergic
Figure 1. Cloning and Characterization of BAG5
Neurons after Injury
(A) Sequence of cloned rat BAG5 aligned with human and mouseTo identify molecular mediators of dopaminergic neuro- sequences. The four BAG domains are shaded, and a putative
degeneration, we employed differential display analysis “short” fifth BAG domain (Briknarova et al., 2002) is underlined.
following the unilateral transection of the axons of dopa- Substituted residues in BAG5(DARA) are indicated with an asterisk.
(B) Northern blots of BAG5 expression in rat and human.minergic SNpc neurons within their projection pathway,
(C) In situ hybridization (ISH) of adult rat brain using a BAG5-specificthe medial forebrain bundle (MFB), in rat. The partial
antisense radiolabeled probe. The lower panel is a representativecDNA of a transcript that increased in the SNpc when
ISH using a control sense probe.compared to the contralateral untransected side at 24 (D) Combined ISH and TH immunohistochemistry (IHC) in SNpc of
hr postaxotomy (see the Supplemental Data at http:// rat brain using a DIG-BAG5 probe shows that TH neurons are also
www.neuron.org/cgi/content/full/44/6/931/DC1/) was BAG5-mRNA (arrows, upper panels). The lower panels show a
representative combined ISH and IHC using a control sense BAG5expanded by RT-PCR and RACE. The full-length cDNA
probe. The upper and middle panels are from the SNpc ipsilateralencoded for a 447 amino acid protein with high identity
and contralateral to MFB axotomy (MFBx), respectively.to human BAG5 (90.4% identity; GenBank accession
(E) Quantitative analysis of ISH signal density in the SNpc at 24 hrnumber NM_004873) and mouse BAG5 (bcl-2-associ- postaxotomy (mean  SEM; **p  0.001; paired Student’s t test;
ated athanogene 5) (93.7% identity; GenBank accession n  4; three sections per animal).
number XM_127149) (Figure 1A).
Using species-specific probes directed against the
open reading frame of BAG5, we identified two tran-
scripts of BAG5 that were widely and differentially ex-
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pressed in multiple tissue types, including rat and hu-
man brain (Figure 1B). In situ hybridization (ISH) analysis
in rat brain using an antisense cRNA probe directed
against rat BAG5 revealed BAG5 expression in cortex,
hippocampus, red nucleus, and the SNpc (Figure 1C,
upper panel). A control sense cRNA probe did not reveal
any structure-specific signal above background (Figure
1C, lower panel). ISH with digoxygenin (DIG)-labeled
antisense rat BAG5 probes combined with immunohis-
tochemistry (IHC) for tyrosine hydroxylase (TH), amarker
for dopaminergic neurons, demonstrated that BAG5
mRNA was expressed in the dopaminergic neurons of
the SNpc (Figure 1D). We also verified the increase in
BAG5 expression in these neurons at 24 hr following
MFB axotomy both qualitatively (Figure 1D, upper panel
versus middle panel) and quantitatively (Figure 1E).
We used polyclonal antibodies directed against BAG5
to examine BAG5 protein expression. The specificity
of the BAG5 antibody was confirmed by Western blot
analysis of cell lysates from the dopaminergic cell line
SH-SY5Y transfected with N-terminal FLAG epitope-
tagged BAG5 (FLAG-BAG5) (Figure 2A). Both anti-FLAG
and anti-BAG5 antibodies recognized a band with the
predicted molecular weight. Preabsorption of the anti-
BAG5 antibody with its corresponding peptide immuno-
gen competed out the signal. Probing lysates from
mouse andhumanbrain revealed abandof the expected
molecular weight of approximately 51 kDa (Figure 2B,
upper panel); preincubation of the anti-BAG5 antibody
with its corresponding peptide immunogen also com-
peted out the signal as seen by Western blot (Figure
2B, lower panel) and immunohistochemistry (Figure 2C).
The anti-BAG5 antibody also recognized rat BAG5, al-
beit with decreased sensitivity and occasionally a minor
band of approximately 35 kDa in BAG5-transfected cell
lysates and tissue lysates (data not shown). In mouse
and rat SNpc, BAG5 immunoreactivity was found in all
TH-immunopositive (TH) dopaminergic neurons, as
well as some TH-immunonegative (TH) neurons (Fig-
ures 2D and 2E). Similarly, in human SNpc from a patient
with diffuse Lewy body (DLB) disease, a neurodegenera-
tive disorder similar to PD, BAG5 immunoreactivity was
found in TH neurons (Figure 2F). -synuclein is a major
component of LBs (Spillantini et al., 1997), and we found
BAG5 immunoreactivity in -synuclein immunoreactive
neurons (Figure 2G) and localized within all LBs (Figure
2H). Our finding that BAG5 expression is induced follow-
Figure 2. BAG5 Protein Is Expressed in the SNpc of Rodent anding dopaminergic neuron injury and is localized within
Human Braindopaminergic neurons and LBs led us to hypothesize
(A) Western blot (WB) of transfected SH-SY5Y lysate (control [] orthat BAG5 may play a role in neurodegeneration.
pDEST-FLAG-BAG5 vector []) probed with anti-BAG5 and anti-
FLAG. Preabsorption of anti-BAG5 antibody with BAG5 peptide im-BAG5 Interacts with and Inhibits the Molecular
munogen is shown on the right. (B) WB of mouse brain and human
Chaperone Hsp70 brain lysates using the anti-BAG5 antibody. (C) IHC of human cortex
Since other BAG family proteins interact with the chap- with anti-BAG5 (left panel) or preabsorbed anti-BAG5 (right panel).
erone Hsp70 (Briknarova et al., 2001; Hohfeld and IHC of mouse (D) and rat (E) SNpc shows BAG5 immunoreactivity
(green) colocalized with TH neurons (red). BAG5 immunoreactivityJentsch, 1997; Sondermann et al., 2001; Takayama et
colocalizes with TH immunoreactivity throughout the SNpc and ven-al., 1997; Zeiner et al., 1997), a protein known to be
tral tegmental area (VTA) of midbrain ([E], right panel). (F) BAG5present in LBs (Auluck et al., 2002; McLean et al., 2002)
immunoreactivity (green) is colocalized in TH neurons (red) in theand to prevent both protein aggregation and neurode-
SNpc from a patient with DLB. (G) BAG5 immunoreactivity (green)
generation (Adachi et al., 2003; Auluck et al., 2002; Cum- colocalizes in -synuclein neurons (red) in human DLB SNpc. (H)
mings et al., 2001; Sherman and Goldberg, 2001), we BAG5 immunoreactivity is also present in -synuclein perinuclear
tested whether BAG5 also interacts directly with Hsp70. Lewy bodies. Scale bars, 50 m (C), 10 m (D and E), and 20 m
(F–H). Blue staining in (D)–(H) is the nuclear stain Hoechst 33342.To test this, we performed in vitro GST pull-down assays
Molecular weight markers are shown in kDa.(PDAs) using recombinant fusion proteins.
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Figure 3. BAG5 Is a Cochaperone of Hsp70
(A) GST-BAG5 pull-down assay with His-Hsp70, His-Hsp70 ATPase domain, His-Hsp70 PBD, or human brain SNpc lysate (400 g). (B) GST-
Hsp70 pull-down assay from human brain SNpc lysate shows Hsp70 binding to endogenous BAG5. (C) Coimmunoprecipitation of endogenous
Hsp70 and BAG5 from human brain lysate (2 mg). (D) Luciferase refolding assay in HEK293T cells. (E) BAG5 associates with Hsp70 and itself
as shownby coimmunoprecipitation ofGFP-BAG5andFLAG-BAG5 from transfectedHEK293T lysate. The asterisk indicates the immunoglobulin
heavy chain. (F) GST-BAG5 and GST-BAG5(DARA) pull-down assays from HEK293T cell lysates transfected with GFP, GFP-BAG5, or GFP-
BAG5(DARA). Inputs are shown in the lower Western blot (WB). (G) Luciferase refolding assay in HEK293T cells shows BAG5(DARA) mitigates
BAG5 inhibition of Hsp70-mediated refolding of thermally inactivated luciferase (*p  0.05; Student’s t test). Representative WBs are shown
above the graph. For (A)–(G), representative results from three experiments are shown.
We found that GST-BAG5, like GST-BAG1, pulled the ATPase domain of Hsp70 is both necessary and
sufficient for the interaction between BAG5 and Hsp70.down full-length Hsp70 in vitro, whereas GST-alone did
not (Figure 3A). To identify the region of Hsp70 that To further confirm the specificity of the interaction
between BAG5 and Hsp70, we aligned its BAG domainsmediates the interaction with BAG5, we generated His-
Hsp70 deletion constructs containing only the ATPase with the BAG domain of BAG1 to identify conserved
amino acids. Based on our alignment and the crystaldomain (ATPase) or protein binding domain (PBD) of
Hsp70. Both GST-BAG5 and GST-BAG1, but not GST- structure of the BAG domain of BAG1 bound to the
Hsp70 ATPase domain (Sondermann et al., 2001), wealone, pulled down the Hsp70 ATPase domain in vitro.
In contrast, GST-BAG5, GST-BAG1, and GST-alone did substituted the conserved aspartate (D) and arginine (R)
with alanine (A) in all four predicted BAG domains bynot pull down the Hsp70 PBD (Figure 3A). Therefore,
BAG5 and Dopaminergic Neuron Degeneration
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site-directed mutagenesis to generate the mutant and GFP-BAG5(DARA). Similar to results from Figure
3E, GST-BAG5 and GST-BAG5(DARA) interacted withBAG5(DARA) (Figure 1A). Consistent with predictions
from previous structural studies (Briknarova et al., 2001, both GFP-BAG5 and GFP-BAG5(DARA), whereas only
GST-BAG5 interacted with Hsp70 (Figure 3F). To deter-2002; Sondermann et al., 2001), substitution of these
conserved residues in all four BAG domains abolished mine if this association has a functional consequence,
we cotransfected BAG5 and BAG5(DARA) together inthe interaction with full-length Hsp70 and the Hsp70
ATPase domain in PDAs using GST-BAG5(DARA). Fur- the luciferase refolding assay described above and
found that the mutant BAG5(DARA) inhibits the effectthermore, we found that GST-BAG5 associated with en-
dogenous Hsp70 in human brain lysate, while GST alone of BAG5 on Hsp70-mediated refolding of the luciferase
(Figure 3G). Therefore, complexes of BAG5 that containor the mutant GST-BAG5(DARA) did not (Figure 3A). In
the converse experiment, the GST-Hsp70 fusion protein BAG5(DARA) are unable to bind Hsp70 and may inhibit
BAG5 activity.also associated with endogenous BAG5 (Figure 3B). We
confirmed the physical association between BAG5 and
Hsp70 in vivo by coimmunoprecipitation from human BAG5 Interacts Directly with Parkin
brain lysate (Figure 3C). Thus, BAG5 interacts with In brain, Hsp70 associates with parkin (Imai et al., 2002).
Hsp70 in vitro and in vivo, and substitution of select Because of the importance of parkin in the pathogenesis
residues within the BAG domains is sufficient to abolish of PD and its association with Hsp70, we tested whether
this interaction. BAG5 associates in a complex with Hsp70 and parkin.
We next examined the functional consequence of the Thus, we cotransfected GFP-parkin with FLAG-BAG5 or
interaction between Hsp70 and BAG5. Other BAG family FLAG-BAG5(DARA) and His-Hsp70 in HEK293T cells.
proteins, including BAG1, are cochaperones of Hsp70 Immunoprecipitation (IP) of GFP-parkin resulted in the
and can negatively regulate the ability of Hsp70 to refold coimmunoprecipitation of both Hsp70 and BAG5 or
misfolded proteins both in vitro (Hohfeld and Jentsch, BAG5(DARA) (Figure 4A). Furthermore, IP of GFP-parkin
1997; Takayama et al., 1997; Zeiner et al., 1997) and resulted in the coimmunoprecipitation of BAG5 or BAG5
in vivo (Nollen et al., 2001). Therefore, we hypothesized (DARA) in the absence of overexpressed Hsp70.
that BAG5 could also modulate Hsp70 chaperone func- To further examine the nature of the association be-
tion. Using a previously described system to investigate tween parkin, Hsp70, and BAG5, we performed in vitro
the effect of BAG1 on Hsp70 chaperone activity in cells pull-down experiments using GST-Hsp70, GST-BAG5,
(Nollen et al., 2000, 2001), we examined the effect of or GST-BAG5(DARA) with recombinant N-terminal His-
BAG5 on Hsp70 activity. We transiently cotransfected tagged parkin. GST-Hsp70, GST-BAG5, and GST-BAG5
Hsp70 and a luciferase reporter into HEK293T cells with (DARA) all interacted directly with His-parkin, whereas
BAG1, BAG5, or the mutant BAG5(DARA). Luciferase GST-alone did not (Figure 4B). Thus, BAG5 can interact
activity was thermally inactivated, and its reactivation by directly with parkin in the absence of Hsp70.
Hsp70 wasmeasured at 30 min intervals over 2 hr. By 2 hr We sought to further dissect the interaction between
postinactivation, BAG5 and BAG1 significantly diminished BAG5 and parkin using a series of N-terminal GFP-
Hsp70-mediated luciferase reactivation, whereas the mu- tagged parkin deletion constructs (Figure 4C). The par-
tant BAG5(DARA) had no significant effect (Figure 3D). kin deletion constructs were individually transfected in
These results show that BAG5 negatively regulates the HEK293T cells, and PDAs were performed using GST-
chaperone activity of Hsp70. BAG5. BAG5 associated with both the N-terminal and
C-terminal deletion constructs of parkin. Within the N ter-
minus of parkin, the BAG5 interaction was furtherBAG5 Associates with Itself
mapped exclusively to the linker region of parkin (Figureand with the Mutant BAG5(DARA)
4D). In agreement with previous results (Imai et al., 2002;Takayamaet al. (1997) have suggested aminimal hetero-
Tsai et al., 2003), Hsp70 binding was limited to the C ter-tetramer stoichiometry (2:2) for the BAG1-Hsp70 inter-
minus of parkin (data not shown). Taken together withaction and have confirmed dimer formation by BAG1
the findings from the coimmunoprecipitation experi-alone. Therefore, we tested whether BAG5 may associ-
ments and in vitro PDAs described above, these resultsate with itself by cotransfecting N-terminal GFP-tagged
establish that BAG5, Hsp70, and parkin may associateBAG5 (GFP-BAG5) with FLAG-BAG5 in HEK293T cells.
in a complex. Furthermore, BAG5 can interact directlyCoimmunoprecipitationofGFP-BAG5but notGFPalone
with parkin in the absence of Hsp70.with FLAG-BAG5 suggested that BAG5 can associate
with itself (Figure 3E, lane 3). Furthermore, GFP-BAG5
(DARA) also coimmunoprecipitated with FLAG-BAG5, BAG5 Inhibits Parkin E3 Activity
Parkin, like other E3s, can undergo autoubiquitinylationsuggesting that site-directed substitution within the
BAG domains does not significantly alter the conforma- (Chung et al., 2004; Staropoli et al., 2003; Zhang et al.,
2000), and parkin E3 activity may be modulated bytion of the mutant BAG5(DARA) (Figure 3E, lane 5). In-
deed, both GFP-BAG5 and GFP-BAG5(DARA) coimmu- Hsp70 (Imai et al., 2002; Tsai et al., 2003). To investigate
the potential role of BAG5 on parkin E3 activity, wenoprecipitated with FLAG-BAG5(DARA) (Figure 3E, lanes
4 and 6, respectively). We also confirmed that Hsp70 examined the autoubiquitinylation of parkin in the pres-
ence or absence of BAG5 and/or Hsp70 in vitro. GST-coimmunoprecipitated with FLAG-BAG5 and not FLAG-
BAG5(DARA) (Figure 3E, lanes 1, 3, and 5 versus 2, 4, parkin but not GST-alone underwent in vitro autoubiqui-
tinylation in the presence of E1 and the E2s Ubc6Cand 6).We further demonstrated the interaction between
BAG5and itself, andBAG5and themutantBAG5(DARA), and Ubc7 (Imai et al., 2001) as detected by anti-ubiquitin
antibodies (Figure 4E). The removal of either ubiquitinusing PDAs in cell lysates transfected with GFP-BAG5
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Figure 4. BAG5 Interacts Directly with Parkin and Inhibits Parkin E3 Activity
(A) BAG5 associates with both parkin and Hsp70 as shown by coimmunoprecipitation from lysates of transfected HEK293T cells. (B) GST
pull-down assay demonstrating that BAG5, BAG5(DARA), and Hsp70 directly interact with His-parkin. (C) Schematic of parkin deletion
constructs. (D) GST-BAG5 pull-down assays from HEK293T cell lysate transfected with indicated GFP-parkin deletion constructs. (E) In vitro
ubiquitinylation assay shows that BAG5 inhibits parkin autoubiquitinylation. (F) Ubiquitinylation assay in transfected HEK293T cells shows
that parkin enhances the ubiquitinylation of synphilin (FLAG-sph1). (G) Ubiquitinylation assays in transfected HEK293T cells show that
both BAG5 and BAG5(DARA) inhibit parkin-mediated ubiquitinylation of the substrate synphilin. (A)–(G) are representative results of three
independent experiments.
or the E2s Ubc6C and Ubc7 prevented autoubiquitiny- decrease in the amount of immunoprecipitated ubiquiti-
nylated synphilin was observed (Figure 4G). Similarly,lation of parkin. The addition of His-Hsp70 alone did
not affect autoubiquitinylation of parkin, whereas the we tested the mutant BAG5(DARA), which retains the
ability to directly interact with parkin, and found that itaddition of His-BAG5 alone significantly inhibited autou-
biquitinylation. Furthermore, the addition of Hsp70 was could also significantly inhibit parkin-mediated ubiquiti-
nylation of synphilin (Figure 4G). Therefore, BAG5 is aunable to rescue the BAG5-mediated inhibition of auto-
ubiquitinylation of parkin (Figure 4E). Parkin ubiquitinyla- putative inhibitor of parkin E3 activity.
tion was confirmed by reprobing the blot with an anti-
parkin antibody (data not shown). The integrity and BAG5 Promotes Parkin Sequestration
through the Inhibition of Hsp70equivalent loading of all fusion proteins were verified by
Ponceau S staining (Figure 4E). Taken together, these Proteasomal inhibition mediates the sequestration of
parkin within perinuclear protein aggregates similar todata demonstrate that BAG5 can directly inhibit parkin-
mediated autoubiquitinylation independently of Hsp70. the LBs of PD (Ardley et al., 2003; Junn et al., 2002;
Muqit et al., 2003; Tsai et al., 2003; Winklhofer et al.,Parkin has been shown to ubiquitinylate several sub-
strates including the-synuclein interacting protein syn- 2003). In experiments similar to that of Junn et al. (2002),
we transfected HEK293T cells with GFP-parkin andphilin (Chung et al., 2001, 2004). We also observed an
enhancement in the ubiquitinylation of C-terminal FLAG- treated the cells with MG132 to initiate the formation of
protein aggregates (Figure 5A). We confirmed that thetagged synphilin (FLAG-sph1) when cotransfected with
parkin in HEK293T cells treated with the proteasome perinuclear parkin protein aggregates were immunore-
active for ubiquitin, andwe found that Hsp70 immunore-inhibitor MG132 (Figure 4F). A BAG5 dose-dependent
BAG5 and Dopaminergic Neuron Degeneration
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Figure 5. BAG5 Prevents Hsp70-Mediated Inhibition of the Formation of Parkin-Containing Protein Aggregates
(A) Parkin is sequestered in protein aggregates following proteasome inhibition by MG132 in HEK293T cells (arrows). (B) Parkin-containing
protein aggregates are also immunoreactive for BAG5 and ubiquitin (left panels) and are surrounded by immunoreactivity for Hsp70 (right
panels). Scale bars, 10 m. (C) BAG5 inhibits Hsp70-mediated prevention of parkin aggregation, whereas BAG5(DARA) does not. (D) The
mutant BAG5(DARA) mitigates BAG5-mediated inhibition of Hsp70 in the parkin aggregation assay. Corresponding representative WBs are
shown above the graphs in (C) and (D). (E) U6_shRNA_b5 depresses FLAG-huBAG5 protein expression but is unable to depress FLAG-rtBAG5
expression as shown by WBs. Lower panels show that U6_shRNA_b5 depresses GFP-BAG5 expression in HEK293T cells, whereas empty
vector (Control) and an unrelated shRNA (U6_shRNA_control) do not. (F) U6_shRNA_b5 but not U6_shRNA_control depresses endogenous
BAG5 mRNA and protein expression in HEK293T cells as shown by RT-PCR and WB. (G) U6_shRNA_b5-mediated depression of BAG5
significantly decreases the relative sequestration of parkin in protein aggregates, whereas U6_shRNA_control does not. Protein aggregation
in the graph is relative to aggregation of GFP-parkin alone. (C)–(G) are representative results of at least three independent experiments; for
graphs, mean  SEM; *p  0.05; **p  0.001 (Student’s t test; Bonferroni-corrected; n.s., not significant).
activity was localized mainly at the periphery of the ag- Thus, we examined whether Hsp70 and BAG5 had an
effect on the formation of parkin-containing perinucleargregate (Figure 5B) as previously described (Junn et al.,
2002). We found that BAG5 immunoreactivity was also aggregates. The cotransfectionofBAG5orBAG5(DARA)
alone with GFP-parkin did not influence the formationcolocalized within these LB-like aggregates (Figure 5B)
as was -synuclein and synphilin (data not shown). Fur- of parkin-containing protein aggregates. Cotransfection
of Hsp70 with GFP-parkin prior to proteasome inhibitionthermore, in agreement with previous studies (Ardley et
al., 2003; Junn et al., 2002), 40%  3% of GFP-parkin significantly reduced the sequestration of parkin within
aggregates to only 6%  2% of GFP-parkin cells (p cells contained aggregates after MG132 treatment. To
verify that the sequestration of parkin within protein ag- 0.001; Student’s t test). However, BAG5 significantly
inhibited the ability of Hsp70 to prevent aggregation,gregates was specific to parkin, we transfected cells
with GFP alone and found that less than 1% of cells whereas cotransfection of the mutant BAG5(DARA) did
not (Figure 5C). Given that the mutant BAG5(DARA) in-contained any detectable inclusions (Figure 5C).
The solubility of parkin and its mutants within a cell hibited the effect of BAG5 on Hsp70 (Figure 3G), we
tested whether the coexpression of BAG5(DARA) couldcan beenhancedby the coexpressionof the chaperones
Hsp70 and Hsp40 with parkin (Winklhofer et al., 2003). also mitigate BAG5 inhibition of Hsp70-mediated sup-
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pression of parkin sequestration. Indeed, we found a HEK293T cells, we observed a significant accumulation
and aggregation of GFPu relative to those cells cotrans-significant decrease in the number of GFP-parkin-con-
taining protein aggregates when BAG5 was cotrans- fected with empty vector (Figures 6A and 6B). To ensure
similar transfection efficiency between conditions, wefected with BAG5(DARA) (Figure 5D). The expression
levels ofGFP-parkin were similar in all conditions tested. used DsRed and 	-galactosidase as transfection con-
trols. Taken together, our results suggest that the accu-Taken together, these data suggest that BAG5, through
its inhibitionofHsp70, canpromoteparkin sequestration mulation of synphilin alone is sufficient to induce protea-
some inhibition as measured by the accumulation ofand enhance the formation of LB-like protein aggre-
gates. GFPu.
The GFPu reporter is not a substrate of parkin, and
parkin has been shown to reduce proteasome impair-shRNA-Mediated Knockdown of BAG5 Inhibits
ment due to substrate accumulation as measured bythe Sequestration of Parkin
the GFPu reporter system (Petrucelli et al., 2002; TsaiTo further validate the functional role of BAG5 as an
et al., 2003). Similarly, we found that parkin mediated aenhancer of parkin sequestration in protein aggregates,
significant decrease in GFPu accumulation due to syn-we employed short hairpin RNA (shRNA)-mediated
philin expression (Figure 6C). BAG5 reversed the inhibi-“knockdown” (Paddison et al., 2002) of BAG5 and exam-
tion of proteasome dysfunction by parkin and resultedined itseffecton thesequestrationofparkin.U6_shRNA_b5,
in a significant increase in the accumulation of GFPu,a U6 promoter-driven shRNA directed against human
whereas cotransfection of the mutant BAG5(DARA) orBAG5, was able to significantly depress the expression
the chaperone Hsp70 resulted in a significant decreaseof transfected FLAG-tagged human BAG5 in HEK293T
in the accumulation of GFPu due to synphilin. Overex-cells, whereas a U6_shRNA_control vector targeting lu-
pression of BAG5 alone also resulted in a significantciferase could not (Figure 5E, upper panel). Also,
increase in the accumulation of GFPu due to synphilincotransfection of U6_shRNA_b5 with N-terminal GFP-
expression (data not shown). Furthermore, cotransfec-tagged BAG5 in HEK293T cells depressed the expres-
tion of the inhibitory mutant BAG5(DARA) with BAG5sion of GFP-BAG5 protein, whereas U6_shRNA_control
mitigated proteasome dysfunction as measured byhad no effect on GFP-BAG5 (Figure 5E, lower panels).
GFPu accumulation (Figure 6D). Taken together, ourNext,we tested ifU6_shRNA_b5coulddepress theendog-
data suggest that BAG5maycontribute in part to protea-enoushuBAG5 in cells, andwe found that U6_shRNA_b5
some impairment, through the inhibition of parkin.significantly depressed the relative expression of both
Parkin has also been shown to prevent cell death bothendogenous BAG5 mRNA and protein, whereas U6_
in cell lines and in vivo (Imai et al., 2000, 2001; Kim etshRNA_control did not (Figure 5F). We then examined
al., 2003; Oluwatosin-Chigbu et al., 2003; Petrucelli etthe relative effect of shRNA-mediated BAG5 knockdown
al., 2002; Yang et al., 2003). Therefore, we sought toon the sequestration of parkin in protein aggregates.
determine whether the interaction between parkin andCotransfection of U6_shRNA_b5with GFP-parkin signif-
BAG5 has consequences on cell survival. As previouslyicantly inhibited the sequestration of parkin in aggre-
reported by others (Chung et al., 2004; Ihara et al., 2003),gates to 50%  5% relative to GFP-parkin alone,
coexpression of synphilin and wild-type -synuclein inwhereas U6_shRNA_control had no significant effect
SH-SY5Y cells in the presence of the irreversible protea-(Figure 5G).
some inhibitor lactacystin results in increasedcell death,To confirm that our observed knockdown effect was
which can be suppressed by parkin (Figure 6E, leftdue to the specific depression of BAG5, we performed
panel). The protective effect of parkin was significantlyfunctional rescue experimentswith rtBAG5,which ishighly
reduced by coexpression of BAG5 (Figure 6E, left panel),homologous to huBAG5 but resistant to U6_shRNA_b5-
while the coexpression of BAG5 alone with synphilinmediated knockdown (Figure 5E). Since BAG5 may pro-
and -synuclein expression in the presence of lactacys-mote parkin sequestration through its inhibition of
tin did not significantly enhance cell death (Figure 6E,Hsp70 (Figure 5C), we first examined if rtBAG5 also
right panel). To further validate our results, we used ourmitigated Hsp70-mediated inhibition of parkin seques-
U6_shRNA_b5 construct to depress the expression oftration in protein aggregates. Indeed, coexpression of
BAG5 and found a significant decrease in cell death,rtBAG5 with Hsp70 and parkin prevented Hsp70-medi-
whereas expression of a U6_shRNA_control constructated inhibition of parkin sequestration. Significantly,
had no effect (Figure 6E, middle panel). The specificityrtBAG5 was able to functionally rescue the loss of hu-
of this effect was demonstrated with functional rescueBAG5 inhibition of Hsp70 function in the presence of
by coexpressing rat BAG5 with the U6_shRNA_b5 con-U6_shRNA_b5 (Figure 5G). Taken together, these data
struct. Finally, the mutant BAG5(DARA) was found toconfirm that BAG5 has a functional role in the sequestra-
suppress both the inhibitory effect of BAG5 on parkintion of parkin in protein aggregates.
(Figure 6E, left panel) and when expressed alone (Figure
6E, right panel).BAG5 Inhibits Parkin-Mediated Suppression
of UPS Dysfunction and Cell Death
A GFPu reporter construct (Bence et al., 2001) allows BAG5 Enhances Dopaminergic
Neurodegeneration In Vivofor the measurement of proteasomal activity in living
cells. GFPu has been shown to rapidly accumulate in Our data implicate BAG5 as a negative modulator of
parkin and Hsp70, two molecules with known neuropro-settings of UPS dysfunction due to the expression of
mutant proteins associated with neurodegenerative dis- tective properties. Because we cloned BAG5 as an
upregulated differentially expressed transcript in the rateases (Bence et al., 2001; Petrucelli et al., 2002; Tsai et
al., 2003). Upon cotransfection of synphilin with GFPu in MFB axotomy model of dopaminergic neuron injury, we
BAG5 and Dopaminergic Neuron Degeneration
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Figure 6. BAG5 Mitigates Parkin-Mediated
Inhibition of Proteasome Stress and Cell
Death
(A) Synphilin (sph1) enhances the accumula-
tion of GFPu (upper panels). DsRed (middle
panels) is a transfection control, and Hoechst
33342 (lower panels) shows total cell num-
bers in the same field. (B)WB shows a synphi-
lin-mediated dose-dependent increase in
GFPu accumulation. (C) BAG5 prevents par-
kin-mediated rescue of GFPu accumulation
due to synphilin. (D) BAG5(DARA) mitigates
the effect of BAG5 on GFPu accumulation.
Graphs in (C) and (D) show 	-galactosidase
normalized GFPu signal (mean  SEM; **p 
0.001; n.s., not significant; Student’s t test)
and corresponding WB. Corresponding WBs
of each condition are shown above the graph.
(E) BAG5 prevents parkin-mediated inhibition
of cell death. Graphs show cell death ob-
served in SH-SY5Y cells transfected with
sph1 and synuclein (syn) and treated with the
irreversible proteasome inhibitor lactacystin
(15 M) (mean SEM; *p 0.05; **p 0.001;
n.s., not significant; Student’s t test; Bonfer-
roni-corrected).
next examined whether BAG5 can enhance cell death nucleus (MTN) in rat following the unilateral injection of
virus in the ipsilateral striatum as we have describedin vivo. A FLAG-BAG5-expressing adenovirus (Ad.BAG5),
a FLAG-BAG5(DARA)-expressing adenovirus [Ad.BAG5- previously (Crocker et al., 2001; Smith et al., 2003). Viral
expression in the SNpc was verified by immunohisto-(DARA)], and a control adenovirus (Ad.GFP) were con-
structed. The expression of both FLAG-BAG5 and chemistry. FLAG-BAG5 or FLAG-BAG5(DARA) immuno-
reactivity was detected in TH dopaminergic neuronsFLAG-BAG5(DARA) was verified by Western blot analy-
sis of infected cell lysates using both anti-FLAGantibod- at 4 weeks postinjection (Figure 7B).
To determine whether BAG5 enhances the loss ofies (Figure 7A) and anti-BAG5 antibodies (data not
shown). Targeted overexpression of adenovirus was dopaminergic neurons following injury, we performed
MFB axotomy 1 week after injection of Ad.GFP, Ad.BAG5,achieved in the SNpc at the level of the medial terminal
Neuron
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Figure 7. Adenovirus-Mediated Expression of BAG5 in the SNpc Enhances Dopaminergic Neurodegeneration Postaxotomy and in the MPTP
Model of PD
(A) WB of lysates of SH-SY5Y infected with Ad.BAG5 and Ad.BAG5(DARA). (B) IHC showing expression of FLAG-BAG5(DARA) and FLAG-
BAG5 in the SNpc of rats ipsilateral to the adenovirus-injected striatum and not in the contralateral SNpc (Control). (C) TH immunoreactivity
in control SNpc and lesioned SNpc 3 days and 7 days postaxotomy in rats injected with adenovirus. (D) Quantitation of TH-positive neurons
as a percent of the contralateral unlesioned. (E) IHC showing expression of adenovirus in the SNpc of mice ipsilateral to the injected striatum
and not in the contralateral SNpc (Control). (F) TH immunoreactivity in the SNpc ipsilateral to injection with adenovirus in mice at 2 weeks
following treatment with saline or MPTP. (G) Quantitation of TH-positive neurons in the adenovirus-injected SNpc relative to contralateral
SNpc. For graphs, mean  SEM; *p  0.05; **p  0.001 (Student’s t test; Bonferroni-corrected; n  3–7).
or Ad.BAG5(DARA) and examined the degree of dopa- rahydropyridine (MPTP) model of PD (Dauer and Przed-
borski, 2003; Vila and Przedborski, 2003). Recently, theminergic neuron loss at 3 and7dayspost-MFBaxotomy.
At day 3 postaxotomy, quantitation of the TH neurons loss of parkin function has also been implicated in neu-
ronal death in this model (Chung et al., 2004; Yao et al.,of the treated SNpc relative to the untreated contralat-
eral side revealed no difference in neuronal survival be- 2004). We found that the targeted expression of BAG5
in the SNpc of mice by Ad.BAG5 (Figure 7E) significantlytween animals treated with Ad.BAG5, Ad.BAG5(DARA), or
Ad.GFP (Figure 7C). However, by day 7 postaxotomy, enhanced the loss of dopaminergic neurons in the SNpc
ipsilateral to the intrastriatal viral injection at 2 weeksanimals receiving Ad.BAG5 showed increased death of
dopaminergic neurons, with only 35% 5% of neurons followingMPTP administrationwhen compared to those
animals injected with the control virus Ad.GFP (Figuressurviving relative to control versus 66%  7% (mean 
SEM; p  0.001; Student’s t test) of neurons surviving 7F and 7G). Next, we examined the effect of mutant
BAG5(DARA) (Figure 7E), which we have shown to bindrelative to control in animals receiving Ad.GFP (Figures
7C and 7D). Loss of dopaminergic neurons was verified to and mitigate the inhibitory effects of BAG5 on Hsp70
and parkin function (Figures 3E–3G, 5D, and 6D–6E). Weby cresyl violet staining to rule out the possibility that
TH protein expression was downregulated postaxotomy found that targeted expression of BAG5(DARA) resulted
in a significant increase in dopaminergic neuronal sur-(data not shown).
We next examined the effect of targeted expression vival (Figures 7F and 7G). Therefore, we conclude that
targeted expression of BAG5 in the SNpc enhances do-of BAG5 and the inhibitory mutant BAG5(DARA) in the
SNpc in the well-defined 1-methyl-4-phenyl-1,2,3,6-tet- paminergic neurodegeneration, whereas targeted ex-
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Figure 8. Proposed Model for the Role of
BAG5 in Enhancing Neurodegeneration
pression of the inhibitory mutant BAG5(DARA) in the ity is that BAG5 inhibits parkin by binding and blocking
the RING finger domains at the C terminus of parkin,SNpc suppresses dopaminergic neurodegeneration in
an in vivo model of PD. interfering with its interaction with E2s. A second possi-
bility is that BAG5 may induce conformational changes
in parkin that result in the inhibition of E3 activity.Discussion
The BAG domain consists of three amphiphatic  heli-
ces (Briknarova et al., 2001; Sondermann et al., 2001).We have demonstrated that BAG5, a BAG family mem-
ber whose expression is induced following dopaminer- Recent models of interactions with the BAG domain,
based on both structure and function analysis (Brehmergic neuron injury, is a negative regulator of both Hsp70
and parkin function that sensitizes dopaminergic neu- et al., 2001; Briknarova et al., 2001, 2002; Brive et al.,
2001; Sondermann et al., 2001, 2002), suggest thatrons to injury-induced death. The exact mechanism by
which chaperones such as Hsp70 confer neuroprotec- Hsp70 binding occurs at the second and third  helices,
whereas other BAG domain binding partners bind to thetion in models of neurodegeneration is not yet clear.
Overexpression of Hsp70 can prevent the formation of first and second  helices (Takayama and Reed, 2001).
Thus, binding partners may “compete” for BAG domainprotein aggregates and enhance cell survival in models
of polyglutamine (polyQ) expansion-mediated neurode- binding based on their relative availability (Nollen and
Morimoto, 2002; Song et al., 2001). Once binding occurs,generation in vivo (Adachi et al., 2003; Chan et al., 2000).
In models of PD (Auluck et al., 2002; Klucken et al., the BAG protein may modify the function of its target
protein, as we have demonstrated with the BAG5 inhibi-2004) and certain cases of polyQ expansion-mediated
neurodegeneration (Cummings et al., 2001; Warrick et tion of both parkin and Hsp70.
The role of protein aggregation in the initiation andal., 1999), neuroprotection by Hsp70 can also occur
without affecting protein aggregation. In these latter progression of neurodegenerative disease remains con-
troversial. Indeed, the sequestration of misfolded pro-cases, it is conceivable that inhibition of cell death oc-
curs by Hsp70 directly inhibiting cell death mediators teins into aggregates may initially be part of a protective
cellular response to transient imbalances in protein fold-(Takayama et al., 2003). Here, we show that BAG5 but
not BAG5(DARA) interacts directly with Hsp70, pre- ing and degradation pathways (Sherman and Goldberg,
2001). However, the expression of defective proteinsventing the refolding of misfolded proteins and protein
aggregation in cells. Consistent with this finding, the in familial forms of neurodegenerative disease or the
targeted depression of parkin expression imposes pro-BAG5-Hsp70 interaction is likely to have important func-
tional consequences in vivo, since we observed en- tracted exposure to abnormal conditions which can re-
sult in direct inhibition of the UPS (Bence et al., 2001;hanced cell death in dopaminergic neurons overex-
pressing BAG5. Petrucelli et al., 2002). Similarly, we show that the accu-
mulation of the parkin substrate synphilin can result inA significant proportion of early-onset cases of PD
are associated with mutations that result in the loss of proteasome dysfunction and that BAG5 can enhance
proteasome dysfunction. This feed-forward cycle ofparkin E3 function (Imai et al., 2000, 2001; Shimura et
al., 2000; Zhang et al., 2000). In these cases, it is likely UPS inhibition alone may be sufficient to perturb protein
homeostasis and enhance the sensitivity of cells to sub-that the loss of parkin function leads to the accumulation
of parkin substrates and subsequent UPS dysfunction sequent stress. As aggregates persist and additional
proteins such as parkin and Hsp70 are increasingly mis-leading to neurodegeneration, often in the absence of
protein aggregates (Giasson and Lee, 2003). Further- localized and thus less able to effectively fulfill their roles
in neuroprotection, the likelihood of cell death increases.more, S-nitrosylation-mediated inhibition of parkin ac-
tivity has recently been shown to be a potential link In addition to these formidable liabilities, our studies
implicate BAG5 as a participant in protein aggregation.between the genetic and sporadic forms of PD (Chung
et al., 2004; Yao et al., 2004). Indeed, depression of BAG5 enhances the formation of parkin-containing pro-
tein aggregates, probably through BAG5-mediated inhi-parkin expression in the context of substrate accumula-
tion enhances dopaminergic cell death (Petrucelli et al., bition of Hsp70 chaperone activity, and overrides the
ability of parkin to preserve proteasome function, whereas2002; Yang et al., 2003), whereas overexpression of par-
kin is often neuroprotective (Imai et al., 2000, 2001; Pe- the inhibitory mutant BAG5(DARA) can prevent this ef-
fect.Given thatBAG5(DARA) retains the ability to associ-trucelli et al., 2002; Yang et al., 2003). Here, we show
that BAG5 interacts directly with parkin and that it may ate with wild-type BAG5, our data suggest that the
mechanism of BAG5(DARA) inhibition is likely throughact as a negative modulator of parkin, attenuating the
parkin-mediated preservation of UPS function and cell the neutralization of available BAG5. However, we can-
not rule out the possibility of other contributing mecha-survival. The exact mechanism by which BAG5 inhibits
parkinE3 activity remains tobeelucidated. Onepossibil- nisms, since BAG5(DARA) may retain regulatory activity
Neuron
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Experimental Procedureson those BAG5 binding proteins that interact with the
first  helix of each BAG domain. Our observation that
All reagents were used according to manufacturer’s protocol unlessthe depression of endogenous BAG5 expression by
otherwise stated.
shRNA leads to decreased protein aggregation and syn-
philin/-synuclein-mediated toxicity in cells further sup- Cloning
ports the possibility that BAG5 plays an important role Cloning of BAG5 and other constructs is outlined in the Supplemen-
tal Data at http://www.neuron.org/cgi/content/full/44/6/931/DC1/.in the regulation of aggregate biogenesis and cell death.
Although the exact role of protein aggregates in neuro-
Northern Blotsdegeneration associated with PD has not yet been es-
mRNA Northern blots (Origene) were probed with rat or human Bag5tablished, BAG5may serve as an important link between
cDNA or 	-actin (Ambion) labeled with [32P]ATP (NEN) using the
the chaperone system, theUPS, andprotein aggregates, StripEZ probe NorthernMax-Gly kits (Ambion).
by forming multiprotein regulatory complexes with
Hsp70 and parkin similar to parkin-containing SCF-like ISH, IHC, and Immunocytochemistry
IHC was performed as we have previously described (Crocker etubiquitin ligase complexes (Staropoli et al., 2003). BAG1
al., 2001). Rat BAG5 probes for ISH were labeled using [33P]UTPand BAG3, two other members of the BAG family, have
(NEN) or digoxygenin (DIG) (Roche) via in vitro transcription withalso been recently characterized as potential links be-
SP6 or T7 RNA polymerase (Promega). Immunocytochemistry (ICC)
tween chaperones and the UPS (Alberti et al., 2002; was performed using conditions described by Junn et al. (2002)
Demand et al., 2001; Doong et al., 2003; Luders et al., and Chung et al. (2001), and cells were analyzed using confocal
2000). microscopy (LSM-510 Meta; Zeiss).
Finally, we show that targeted expression of BAG5
Antibodieswithin the SNpc enhances dopaminergic neurodegener-
Tyrosine hydroxylase (Immunostar), -synuclein (BD Bioscience),ation in vivo in an axotomy model of dopaminergic neu-
Hsp70 (monoclonal; Stressgen), FLAG (M2, Cy3-M2, and polyclonal;
ron injury and in the MPTP model of PD. We also show Sigma), His-tag (Amersham), HA-tag (Roche), ubiquitin (Chemicon),
that BAG5(DARA), an inhibitorymutant of BAG5, confers parkin (Cell Signal), GAPDH (Chemicon),	-galactosidase (Promega),
significant neuroprotection in the MPTP model of PD, and GFP (polyclonal; Molecular Probes). BAG5 polyclonal antibod-
ies were generated by Exalpha Biologicals against KLH-conjugatedthus suggesting that BAG5 may play an important role
BAG5(118-134) peptide (Dalton). Affinity-purified antibody was gen-in the loss of dopaminergic neurons. It still remains to be
erated using a sulfhydryl coupling column (Sulfolink Kit; Pierce).determined whether the enhanced neurodegeneration
observed in this study is a unique function of BAG5 or
Cell Culture
if other BAG domain-containing proteins can also act HEK293T, NIH 3T3, and SH-SY5Y cells were maintained in DMEM
as prodeath molecules in the SNpc. Recent evidence growth medium supplemented with 10% fetal bovine serum, 0.5
implicates other BAG family proteins as molecular sen- mg/ml amphotericin B, 100 U/ml penicillin, and 100 mg/ml strepto-
mycin (Invitrogen) at 37
C in 5% CO2.sors that can enhance cell survival by interacting with
available substrates in diverse signalingpathways (Song
Fusion Proteinset al., 2001; Takayama and Reed, 2001). Indeed, trans-
All GST and His fusion proteins were expressed in E. coli and affinity
genic overexpression of BAG1 in mice has been shown purified using Glutathione Sepharose 4B beads and HiTrapColumns
to confer neuroprotection in an animal model of stroke (Amersham), respectively. His-Ubc6C (C-terminal truncated Ubc6)
(Kermer et al., 2003). and His-Ubc7 (Imai et al., 2001) (kind gift of R. Takahashi) were
affinity purified using Ni-NTA Agarose (Qiagen).HowBAG5may differ fromother BAG family members
andhowBAG5maycontribute to the selective sensitivity
PDAs and IPsof dopaminergic neurons will require further investiga-
Samples were harvested in lysis buffer (50 mM Tris-HCl [pH 7.4],tion. If the chaperone response is impaired in stressed
150 mM NaCl, 2 mM EDTA, 1% Triton X-100) supplemented with
dopaminergic neurons as itmay be in other neurodegen- protease inhibitors (Roche). For complete solubilization of the pellet
erative processes (Batulan et al., 2003), it is possible that in synphilin ubiquitinylation experiments, boiling lysis buffer with 1%
the relative amount of available BAG5may be increased. SDSwas used. IPswere performed overnight followed by incubation
with Protein G sepharose beads (Amersham). PDAs were performedIndeed, the levels of Hsp70, BAG protein, and BAG pro-
with equimolar amounts of GST and His fusion proteins for 1 hrtein substrates have already been shown to have signifi-
(4
C). Beads were washed once with lysis buffer and three timescant biological consequences (Song et al., 2001). Loss
with PBS (pH 7.4).
of parkin function, through mutation as in AR-JPD (Ki-
tada et al., 1998) or nitrosylation (Chung et al., 2004; Yao Luciferase Refolding Assay
et al., 2004), results in dopaminergic neurodegeneration. Refolding assays were performed as described by Nollen et al.
(2001) using indicated vectors and normalized for transfection effi-Since BAG5 inhibits parkin activity, it is conceivable that
ciency by 	-galactosidase activity (pSV-	-Galactosidase Controlincreases in the relative amount of available BAG5, by
Vector; Promega).either increased expression or impaired Hsp70 availabil-
ity, may contribute to selective dopaminergic neurode- Parkin Ubiquitinylation Assays
generation. Based on our findings,wepropose amecha- Ubiquitinylation was carried out by incubating 2 g GST or GST-
nism for neurodegeneration in which BAG5 can interact Parkin, 3 g His-BAG5, 3 g His-Hsp70, with mammalian E1 ubiqui-
tin-activating enzyme (Boston Biochem) (180 nM), the E2 ubiquitin-with both parkin and Hsp70, resulting in decreased par-
conjugating enzymes Ubc6C (2 g) and Ubc7 (2 g) (kind gift ofkin and Hsp70 function, two outcomes that are deleteri-
R. Takahashi), and 20 M Ub (Sigma), in 50 mM Tris (pH 7.4), 100ous to cell survival (Figure 8). Given the role of BAG5
mM NaCl, 5 mM MgCl2, 1 mM DTT, 0.5 M Ubiquitin Aldehydein modulating ubiquitinylation, protein aggregation, and (Boston Biochem), and 4 mM ATP. The reaction was incubated at
cell death, it may serve as a useful therapeutic target 37
C for 45 min and resolved by SDS-PAGE. Synphilin ubiquitinyla-
tion assays were performed in HEK293T cells as described by othersfor neurodegenerative diseases such as PD.
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(Chung et al., 2001, 2004). Cells were cotransfected with indicated Auluck, P.K., Chan, H.Y., Trojanowski, J.Q., Lee, V.M., and Bonini,
N.M. (2002). Chaperone suppression of alpha-synuclein toxicity invectors and HA-ubiquitin (kind gift of J. Wrana) and treated with 20
M of the proteasome inhibitor MG132 for 6 hr prior to harvesting. a Drosophila model for Parkinson’s disease. Science 295, 865–868.
Batulan, Z., Shinder, G.A., Minotti, S., He, B.P., Doroudchi, M.M.,
Parkin Sequestration Nalbantoglu, J., Strong, M.J., and Durham, H.D. (2003). High thresh-
Parkin sequestration assays were performed as described by Junn old for induction of the stress response in motor neurons is associ-
et al. (2002) with GFP-parkin andmodifications described in the text. ated with failure to activate HSF1. J. Neurosci. 23, 5789–5798.
Bence, N.F., Sampat, R.M., and Kopito, R.R. (2001). Impairment of
shRNA-Mediated Knockdown of BAG5
the ubiquitin-proteasome system by protein aggregation. Science
Vectors for U6-driven expression of shRNAs were generated from
292, 1552–1555.
a U6 promoter-containing vector template (kind gift of G. Hannon)
Brehmer, D., Rudiger, S., Gassler, C.S., Klostermeier, D.,(for primers, see the Supplemental Data at http://www.neuron.org/
Packschies, L., Reinstein, J., Mayer, M.P., and Bukau, B. (2001).cgi/content/full/44/6/931/DC1/).
Tuning of chaperone activity of Hsp70 proteins by modulation of
nucleotide exchange. Nat. Struct. Biol. 8, 427–432.GFPu Proteasome Reporter Assays
Briknarova, K., Takayama, S., Brive, L., Havert, M.L., Knee, D.A.,The GFPu reporter construct was cotransfected with the indicated
Velasco, J., Homma, S., Cabezas, E., Stuart, J., Hoyt, D.W., et al.vectors in HEK293T cells and lysed at 48 hr using gel loading buffer.
(2001). Structural analysis of BAG1 cochaperone and its interactionsGFPu accumulationwasmeasured by fluorescencemicroscopy and
with Hsc70 heat shock protein. Nat. Struct. Biol. 8, 349–352.WB quantitation relative to transfection controls (DsRed and
	-galactosidase). Briknarova, K., Takayama, S., Homma, S., Baker, K., Cabezas, E.,
Hoyt, D.W., Li, Z., Satterthwait, A.C., and Ely, K.R. (2002). BAG4/
Cell Death Analysis SODD protein contains a short BAG domain. J. Biol. Chem. 277,
Similar to others (Chung et al., 2004), we transfected SH-SY5Y cells 31172–31178.
with the indicated plasmids for 24 hr followed by treatment with Brive, L., Takayama, S., Briknarova, K., Homma, S., Ishida, S.K.,
lactacystin for 18 hr, and cell death was quantified with Hoechst Reed, J.C., and Ely, K.R. (2001). The carboxyl-terminal lobe of Hsc70
33342 (Molecular Probes) and propidium iodide (Molecular Probes). ATPase domain is sufficient for binding to BAG1. Biochem. Biophys.
Res. Commun. 289, 1099–1105.
Intrastriatal Adenovirus Injection, MFB Axotomy,
Chan, H.Y., Warrick, J.M., Gray-Board, G.L., Paulson, H.L., and Bon-and the MPTP Model of PD
ini, N.M. (2000). Mechanisms of chaperone suppression of polyglu-Intrastriatal adenovirus injections were performed in rats and mice
tamine disease: selectivity, synergy and modulation of protein solu-as we have previously described (Crocker et al., 2001; Smith et al.,
bility in Drosophila. Hum. Mol. Genet. 9, 2811–2820.2003) in compliance with the Canadian Council on Animal Care
Chung, K.K., Zhang, Y., Lim, K.L., Tanaka, Y., Huang, H., Gao, J.,guidelines. Adenovirus was generated by subcloning FLAG-BAG5
Ross, C.A., Dawson, V.L., and Dawson, T.M. (2001). Parkin ubiquiti-and FLAG-BAG5(DARA) into AdTrack-CMV using the AdEasy sys-
nates the alpha-synuclein-interacting protein, synphilin-1: implica-tem (Quantum). Ad.GFP was generated using empty AdTrack-CMV
tions for Lewy-body formation in Parkinson disease. Nat. Med. 7,shuttle vector. MFB axotomy in rats, MPTP injections in mice, and
1144–1150.analysis were performed as we have previously described (Crocker
et al., 2001; Smith et al., 2003). Chung, K.K., Thomas, B., Li, X., Pletnikova, O., Troncoso, J.C.,
Marsh, L., Dawson, V.L., and Dawson, T.M. (2004). S-nitrosylation of
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